STADA strengthens oncology offering by launching Oyavas biosimilar
German drugmaker STADA Arzneimittel (SAZ: Xetra) has broadened its specialty oncology portfolio by introducing its Oyavas (bevacizumab) biosimilar upon receiving a pan-European marketing authorization.
A biosimilar to Roche’s (ROG: SIX) Avastin, Oyavas is now available to oncologists and their patients in Germany and the Netherlands, while launches in other European countries will follow soon, depending in part on national pricing and reimbursement clearance.
The Oyavas launches in Germany and the Netherlands come immediately after receipt of a centralized marketing authorization from the European Commission. Under the terms of an agreement with mAbxience, STADA holds the marketing authorization and sales and marketing rights to Oyavas in around 40 European countries, including all 27 European Union member states.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze